Efficacy, as measured by tumor growth inhibition (TGI) was assessed in 3 models of ABC (U2932, RIVA, and OCI-LY10) and two models of GCB (SU-DHL-4 and NU-DHL-1) subtype DLBCL to make an initial assessment of whether response to BCL-2/MCL-1 inhibition can be predicted based on genetic subtyping. Here, BCL2 is linked to diffuse large B-cell lymphoma.